Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in epidermal growth factor receptor (EGFR) exons 19 or 21 confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC).
• While first-line TKI therapy benefits these patients, primary resistance occurs in 10%, and secondary resistance develops in 50% within 9-12 months.
• Current RECIST criteria for progression may be inadequate for EGFR-mutated NSCLC due to significant initial tumor shrinkage and slow relapse kinetics.

Purpose of the Study:

• To review the mechanisms of primary and secondary resistance to EGFR-TKIs in NSCLC.
• To discuss the limitations of RECIST criteria in assessing treatment response in this patient population.
• To explore potential therapeutic strategies for overcoming TKI resistance in NSCLC.

Main Methods:

• Literature review of studies on EGFR mutations, TKI resistance, and treatment outcomes in NSCLC.
• Analysis of established and emerging mechanisms of TKI resistance.
• Discussion of current and potential future treatment paradigms.

Main Results:

• Common secondary resistance mechanisms include EGFR T790M mutation, amplification of other receptor tyrosine kinases (e.g., c-met, HER2, AXL), PI3K/PTEN pathway alterations, and epithelial-mesenchymal transition.
• The optimal clinical strategy for managing TKI resistance remains undefined, with options including continuing TKI, switching to chemotherapy, combination therapy, or novel targeted agents.

Conclusions:

• Understanding resistance mechanisms is crucial for developing effective treatment strategies for EGFR-mutated NSCLC.
• Further research is needed to define optimal therapeutic approaches for patients who develop TKI resistance.
• Personalized treatment strategies targeting specific resistance mechanisms may improve outcomes in NSCLC.